Schizophrenia News and Research

Latest Schizophrenia News and Research

ARYx secures bridge financing, reports decrease in net loss to $3.6M for second-quarter 2010

ARYx Therapeutics, Inc. today announced that it has secured bridge financing to allow ARYx time and resources to potentially complete a transaction that could create significant value for stockholders. ARYx also released its financial results for the second quarter of 2010.

16 Aug 2010

Recent research on schizophrenia published in journal Current Directions in Psychological Science

It has been nearly a century since the term "schizophrenia" was first used to describe what was then considered a hopeless and incurable disorder of thought and emotion. Schizophrenia is still baffling to both scientists and the general public, but it is no longer considered hopeless. Significant advances have been made on several fronts in fathoming and combating this debilitating mental illness-from genetics to neuroscience to the psychosocial aspects of the disorder.

16 Aug 2010

Survey: Majority of U.S. pharmaceutical companies develop drugs for mental illness

Pharmaceutical research and biotechnology companies in New Jersey, California, New York and North Carolina are responsible for 192 of the 313 medicines in development today to treat mental illnesses, a new survey shows.

16 Aug 2010

Management of therapy-resistant schizophrenia

The psychotic symptoms of up to 30% of schizophrenic patients do not respond adequately to treatment with antipsychotic drugs, other than clozapine. These refractory patients are generally among the most disabled of all people with schizophrenia and require special assessment and treatment.

13 Aug 2010

EUROPEAN BIOTECHNICA AWARD finalists announced

The names of the finalists in this year's EUROPEAN BIOTECHNICA AWARD have been announced. The companies Addex Pharmaceuticals (Switzerland), Apeiron Biologics (Austria) and Galapagos Genomics (Belgium) have made it through to the final round.

13 Aug 2010

Exposure to immune proteins during pregnancy increases risk for schizophrenia in offspring

Infections like the flu are common occurrences during pregnancy, and research has shown that children born to mothers who suffered from flu, viruses and other infections during pregnancy have about a 1.5 to 7 times increased risk for schizophrenia. A new study out of Temple University examines what's behind that link.

13 Aug 2010

NAMI calls for $20 billion relief fund to cover mental health needs resulting from oil spill

The National Alliance on Mental Illness has called on Kenneth Feinberg, the independent claims administrator for the $20 billion relief fund created by BP Oil Company, to cover mental health needs resulting from the company's massive oil spill in the Gulf of Mexico.

12 Aug 2010

ACADIA second-quarter net loss decreases to $4.3 million

ACADIA Pharmaceuticals Inc., a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today reported its unaudited financial results for the second quarter ended June 30, 2010.

10 Aug 2010

Alkermes reports $42.3 million revenue for first-quarter fiscal 2011

Alkermes, Inc. today reported financial results for its first quarter of fiscal 2011, which ended on June 30, 2010.

7 Aug 2010

Asynchronous telepsychiatry provides primary-care physicians greater access to psychiatric consultation

A new study by researchers at the UC Davis School of Medicine has found that psychiatrists can accurately assess a patient's mental health by viewing videotaped interviews that are sent to them for consultation and treatment recommendations.

7 Aug 2010

TEMPO study recommends early administration of Azilect in PD patients

Teva Pharmaceutical Industries Ltd. and H. Lundbeck A/S (Lundbeck) today announced newly published long-term data on Azilect(rasagiline tablets) from the TEMPO study and its open-label extension. The findings confirm the long-term efficacy, safety and tolerability of Azilect® in patients with Parkinson's disease (PD) and further demonstrate the benefits obtained with early treatment initiation. The data was published in the June 2010 issue of the International Journal of Neuroscience.

6 Aug 2010

Scientists identify genetic variant that increases risk of schizophrenia

A group of scientists has identified a genetic variant that substantially increases the risk for developing schizophrenia in Ashkenazi Jewish and other populations. The study, published by Cell Press on August 5th in the American Journal of Human Genetics, associates a deletion on chromosome 3 with increased incidence of schizophrenia.

6 Aug 2010

University of Pennsylvania announces recipients of 2010 Templeton Positive Neuroscience Awards

The Positive Psychology Center of the University of Pennsylvania and the John Templeton Foundation have announced the recipients of the 2010 Templeton Positive Neuroscience Awards, $2.9 million given to 15 new research projects at the intersection of neuroscience and positive psychology.

5 Aug 2010

EEG patterns can predict schizophrenia patients' response to clozapine therapy

A commonplace electroencephalography (EEG) test may hold the key to predicting whether a person will respond to certain prescribed drugs, particularly those related to psychiatric conditions.In a study to be published by Clinical Neurophysiology, and now posted online, engineering and health sciences researchers at McMaster University applied machine learning to EEG patterns and successfully predicted how patients with schizophrenia would respond to clozapine therapy.

5 Aug 2010

Ketamine reduces depression in treatment-resistant bipolar disorder: Study

A single intravenous dose of the anesthetic agent ketamine appears to reduce symptoms of depression within 40 minutes among those with bipolar disorder who have not responded to other treatments, according to a report in the August issue of Archives of General Psychiatry, one of the JAMA/Archives journals.

3 Aug 2010

Merck reports strong bottom-line performance in second quarter

Merck & Co., Inc. today announced financial results for the second quarter of 2010. The company reported non-GAAP (generally accepted accounting principles) earnings per share (EPS) for the second quarter of $0.86, which excludes purchase accounting adjustments, merger-related expenses, restructuring costs and the gain on AstraZeneca's asset option exercise. Second-quarter GAAP EPS was $0.24.

2 Aug 2010

COGS receives $10 million renewal grant from National Institute of Mental Health

The six-site Consortium on the Genetics of Schizophrenia (COGS), led by the director of the Schizophrenia Program at the University of California, San Diego School of Medicine, has received a $10 million renewal grant from the National Institute of Mental Health (NIMH), one of the National Institutes of Health. The grant funds an ongoing, multiple-site collaboration examining the genetic architecture of the causes and abnormalities related to schizophrenia.

31 Jul 2010

Intra-Cellular Therapies ITI-007 Phase Ib/II clinical trial for schizophrenia meets primary endpoint

Intra-Cellular Therapies, Inc. today announced the results from a Phase Ib/II clinical trial in patients with schizophrenia with ITI-007, the Company's unique, investigational new drug for the treatment of schizophrenia. The trial met its primary endpoint demonstrating that ITI-007 was safe and well-tolerated in patients with stabilized schizophrenia.

30 Jul 2010

ACADIA initiates new pimavanserin Phase III trial for Parkinson's disease psychosis

ACADIA Pharmaceuticals Inc., a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it has initiated a new Phase III trial designed to evaluate the efficacy, tolerability and safety of pimavanserin as a treatment for patients with Parkinson's disease psychosis (PDP).

30 Jul 2010

NARSAD to honor five young scientists at Annual Klerman and Freedman Awards event

July 30 NARSAD will honor five outstanding researchers at the Annual Klerman and Freedman Awards event in New York City.

29 Jul 2010

Schizophrenia News and Research

Latest Schizophrenia News and Research

ARYx secures bridge financing, reports decrease in net loss to $3.6M for second-quarter 2010

Recent research on schizophrenia published in journal Current Directions in Psychological Science

Survey: Majority of U.S. pharmaceutical companies develop drugs for mental illness

Management of therapy-resistant schizophrenia

EUROPEAN BIOTECHNICA AWARD finalists announced

Exposure to immune proteins during pregnancy increases risk for schizophrenia in offspring

NAMI calls for $20 billion relief fund to cover mental health needs resulting from oil spill

ACADIA second-quarter net loss decreases to $4.3 million

Alkermes reports $42.3 million revenue for first-quarter fiscal 2011

Asynchronous telepsychiatry provides primary-care physicians greater access to psychiatric consultation

TEMPO study recommends early administration of Azilect in PD patients

Scientists identify genetic variant that increases risk of schizophrenia

University of Pennsylvania announces recipients of 2010 Templeton Positive Neuroscience Awards

EEG patterns can predict schizophrenia patients' response to clozapine therapy

Ketamine reduces depression in treatment-resistant bipolar disorder: Study

Merck reports strong bottom-line performance in second quarter

COGS receives $10 million renewal grant from National Institute of Mental Health

Intra-Cellular Therapies ITI-007 Phase Ib/II clinical trial for schizophrenia meets primary endpoint

ACADIA initiates new pimavanserin Phase III trial for Parkinson's disease psychosis

NARSAD to honor five young scientists at Annual Klerman and Freedman Awards event

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Schizophrenia News and Research

Latest Schizophrenia News and Research

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in